Efficacy and Safety of Zanubrutinib in IgA-secerning Lymphoplasmacytic Lymphoma

Abstract

Efficacy and Safety of zanubrutinib in IgA-secerning Lymphoplasmacytic Lymphoma. Journal of Cancer Science and Clinical Therapeutics 6 (2022): 146-151. Abstract Non IgM-Lymphoplasmacytic Lymphoma (LPL) is a rare chronic lymph proliferative disorder with worse outcome with respect to classical LPL and Waldenstrom Macroglobulinemia. Therapeutic options are limited and differently from other indolent lymphomas no specific approved therapies are available. Here we present the case of a IgA-secreting LPL previously treated with 6 lines of therapies including immuno-chemotherapy, proteasome inhibitor and radiotherapy. At the last relapse this patient was